Mateon Therapeutics, in collaboration with Oncotelic, focuses on innovative approaches in immuno-oncology and RNA therapeutics to address cancer and infectious diseases. Their lead candidate, OT-101, is a first-in-class anti-TGF-β RNA therapeutic that has demonstrated efficacy in clinical trials for relapsed or refractory cancer patients. This therapeutic not only targets cancer but also shows potential activity against SARS-CoV-2, highlighting its versatility in treating both oncological and viral conditions. The company is particularly dedicated to improving outcomes for patients with rare pediatric cancers, having received designations for several conditions, including Diffuse Intrinsic Pontine Glioma (DIPG) and Acute Myeloid Leukemia (AML).

In addition to their cancer therapies, Mateon is exploring the use of Pet2DAO, which integrates corporate governance with decentralized autonomous organization (DAO) technology to enhance animal health. This initiative reflects the company's commitment to leveraging innovative governance models to revolutionize healthcare solutions. With over 100 patent applications and a focus on developing first-in-class therapeutics, Mateon Therapeutics aims to make significant advancements in the treatment landscape for both cancer and viral infections.

United States

Mateon Therapeutics is developing OXi4503 for the treatment of acute myeloid leukemia. OXi4503 has a unique dual mechanism of action which causes the release of leukemic stem cells from the bone marrow and enables their destruction.The company is also using artificial intelligence to develop treatments for coronavirus.

Mateon Therapeutics (Merge with Oncotelic)

Company Details